IsoRay Medical, Inc. Introduces Branding of Cesium-131 as Proxcelan(TM) for Use in Prostate Cancer Brachytherapy

RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Medical, Inc. begins the brand introduction of its existing proprietary Cesium-131 prostate cancer brachytherapy seeds at the 26th annual American Association of Physicists in Medicine (AAPM) conference in Minneapolis, MN, July 22-26.

MORE ON THIS TOPIC